These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30357039)

  • 21. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program.
    Weir MR; Slee A; Sun T; Balis D; Oh R; de Zeeuw D; Perkovic V
    Clin Kidney J; 2021 May; 14(5):1396-1402. PubMed ID: 34221371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.
    Oikonomou EK; Suchard MA; McGuire DK; Khera R
    Diabetes Care; 2022 Apr; 45(4):965-974. PubMed ID: 35120199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus.
    Vinke JSJ; Heerspink HJL; de Borst MH
    Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):321-327. PubMed ID: 30958403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control.
    Satoh H
    Diabetol Int; 2018 Oct; 9(4):212-214. PubMed ID: 30603370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canagliflozin and Stroke in Type 2 Diabetes Mellitus.
    Zhou Z; Lindley RI; Rådholm K; Jenkins B; Watson J; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Shaw W; Oh R; Desai M; Matthews DR; Neal B
    Stroke; 2019 Feb; 50(2):396-404. PubMed ID: 30591006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review.
    Rastogi A; Bhansali A
    Diabetes Ther; 2017 Dec; 8(6):1245-1251. PubMed ID: 29076040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
    Watts NB; Bilezikian JP; Usiskin K; Edwards R; Desai M; Law G; Meininger G
    J Clin Endocrinol Metab; 2016 Jan; 101(1):157-66. PubMed ID: 26580237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
    Blevins TC; Farooki A
    Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
    Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Stein P; Desai M; Shaw W; Jiang J; Vercruysse F; Meininger G; Matthews D
    Am Heart J; 2013 Aug; 166(2):217-223.e11. PubMed ID: 23895803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
    Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; de Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V
    Circulation; 2019 Aug; 140(9):739-750. PubMed ID: 31291786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
    Messana JA; Schwartz SS; Townsend RR
    Vasc Health Risk Manag; 2017; 13():43-54. PubMed ID: 28255241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk.
    Erythropoulou-Kaltsidou A; Polychronopoulos G; Tziomalos K
    Diabetes Ther; 2020 Jan; 11(1):7-14. PubMed ID: 31734830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.
    Koshino A; Schechter M; Sen T; Vart P; Neuen BL; Neal B; Arnott C; Perkovic V; Ridker PM; Tuttle KR; Hansen MK; Heerspink HJL
    Diabetes Care; 2022 Nov; 45(11):2644-2652. PubMed ID: 36134918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implications of the CANVAS Study in Reducing Cardiovascular Outcomes.
    Madan Paramasivan A; Purushothaman A; Desouza C
    Curr Diab Rep; 2018 Nov; 18(12):142. PubMed ID: 30397837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.